At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 171 enrolled
Drug / intervention
Sugammadexdrug
Likely dose
Sugammadex 4mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The POUR Study: Effects of Neuromuscular Reversal Agents on Postoperative Urinary Retention (POUR) Following Laparoscopic Inguinal Hernia Repair
In Brief
A Phase 3 clinical trial evaluating Sugammadex for Postoperative Urinary Retention. Completed, enrolled 171 participants across 1 site.
Detailed Summary
The primary aim of this study will be to compare the rate of postoperative urinary retention between patients receiving Sugammadex and those receiving traditional reversal agents
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Urinary Retention
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartApr 2022
Primary CompletionSep 2024
TodayJul 2026
First PostedMar 11, 2022
Enrollment StartApr 13, 2022
Primary CompletionSep 3, 2024
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 4.3 years ago
Interventions
Sugammadexdrug
The dosing for Sugammadex is 4mg/kg for a deep reversal and a 2mg/kg for a standard reversal, which will be more common for this study. Sugammadex comes in 200mg/2mL and 500mg/5mL vials. Because of the variability in weight of the patients and the type of reversal needed (deep vs standard), 140 5mL vials will be required.